Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

We recently published Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups. Verona Pharma plc ...

Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

Merck announced Wednesday it will acquire UK-based Verona Pharma for approximately $10 billion, deepening its commitment to ...

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc.

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...